STOCK WATCH

■ ANGLE rose 10.8pc, or 10p, to 103p after it secured another contract for a new clinical cancer trial with its first major pharma customer.

The Guildford firm, listed on AIM, said the customer has numerous cancer drugs under development and revenues of more than £1bn a year.

Angle’s Parsortix system will analyse how the drugs are working and the additional contract could be worth £1m. Last month Parsortix was backed by the US Food and Drug Administration.